IP Library Granted Patent US 11,459,293
Granted Patent B2
US 11,459,293 · App. 16/758,396 · Granted Oct 4, 2022

Compositions and methods of making expanded hematopoietic stem cells using derivatives of fluorene

Inventors: Jesse Cotari (San Francisco, CA); Timothy Webb (Ontario, CA); Zhan Wang (San Francisco, CA)
Assignee: ImmuneBridge Inc.
C07C233/33A61K35/28C07C225/22C07C235/56C07C251/44C07C271/30C07C275/28C07D309/08A61K31/4709C07C2603/18
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 11,459,293
App. No.
16/758,396
Granted
Oct 4, 2022
Kind
B2
Abstract

This invention is directed to, inter alia, compounds, methods, systems, and compositions for the maintenance, enhancement, and expansion of hematopoietic stem cells derived from one or more sources of CD34+ cells. Sources of CD34+ cells include bone marrow, cord blood, mobilized peripheral blood, and non-mobilized peripheral blood. Also provided herein are compounds of Formula I which are useful in maintaining, enhancing, and expanding of hematopoietic stem cells.

Claims (22)

1. A compound of Formula IIIa1

or a pharmaceutically acceptable salt, hydrate, or solvate thereof; wherein,

R 1 is —NH—C(O)—R 1a NR b —C(O)—R 1a ,

R 1a is selected from the group consisting of C 2-6 alkyl and C 2-6 haloalkyl;

R 2 is —OH; and

the subscript n is 0 or 1.

2. The compound of claim 1 , wherein n is 0.

3. The compound of claim 1 , wherein n is 1.

4. The compound of claim 1 , wherein R 1a is C 2-6 haloalkyl.

5. The compound of claim 1 , wherein R 1a is C 2-6 alkyl.

6. The compound of claim 1 , wherein n is 0 and R 1a is C 2-4 alkyl.

7. The compound of claim 1 , wherein n is 0 and R 1a is C 2-4 haloalkyl.

8. A compound of claim 1 , having the structure

9. A compound of claim 1 , having the structure

or a pharmaceutically acceptable salt thereof.

10. A compound of claim 1 , having the structure

11. A compound of claim 1 , having the structure

or a pharmaceutically acceptable salt thereof.

12. A compound of claim 1 , having the structure

13. A compound of claim 1 , having the structure

or a pharmaceutically acceptable salt thereof.

14. The compound of claim 1 , wherein said compound is selected from the group consisting of

Assignments (3)
CHANGE OF NAME Recorded Jun 15, 2022
From: TRANSFUSION HEALTH, LLC
To: IMMUNEBRIDGE LLC
Reel/Frame 060957/0669 →
CHANGE OF NAME Recorded Jun 15, 2022
From: IMMUNEBRIDGE LLC
To: IMMUNEBRIDGE INC.
Reel/Frame 060450/0246 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded May 12, 2020
From: COTARI, JESSE; WEBB, TIMOTHY; WANG, ZHAN
To: TRANSFUSION HEALTH, LLC
Reel/Frame 052638/0510 →
Continuity (3)
Provisional Application 62578297 · Oct 27, 2017
Provisional Application 62583328 · Nov 8, 2017
Related Publication 20200255371A1 · Aug 13, 2020
Cited By (1)
US 12,698,255